Positive HELIOS-B Phase III study of vutrisiran

30 August 2024

US RNAi therapeutics company Alnylam Pharmaceuticals (Nasdaq: ALNY) today announced what is called positive detailed results from the HELIOS-B Phase III study of vutrisiran, in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM).

However, investors were not convinced, as Alnylam’ shares were down more than 13% at $249.00 in pre-market activity. The summary data did not include details that would have allowed doctors and analysts to comprehensively assess vutrisiran’s performance compared with other treatments for the condition.

The data were presented today in a Hot Line session at the European Society of Cardiology (ESC) Congress 2024, taking place August 30-September 2 in London, UK.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK